

## Zerbaxa® (ceftolozane/tazobactam) - New indication

- On June 3, 2019, the <u>FDA announced</u> the approval of <u>Merck's Zerbaxa (ceftolozane/tazobactam)</u>, for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), caused by the following susceptible gramnegative microorganisms: *Enterobacter cloacae*, *Escherichia coli*, *Haemophilus influenzae*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, and *Serratia marcescens*.
- Zerbaxa is also approved for complicated intra-abdominal infections, used in combination with metronidazole; and complicated urinary tract infections, including pyelonephritis.
- HABP and VABP occur in patients in hospitals or other health care facilities and can be caused by a
  variety of bacteria. According to data from the Centers for Disease Control and Prevention, HABP and
  VABP are currently the second most common type of hospital-acquired infection in the U.S., and are a
  significant issue in patients in the intensive care unit.
- The approval of Zerbaxa's new indication was based on a double-blind study in 726 adult patients hospitalized with HABP/VABP. The study compared Zerbaxa to meropenem for 8 to 14 days of therapy. Efficacy was assessed based on all-cause mortality at day 28 and clinical cure, defined as complete resolution or significant improvement in signs and symptoms of the index infection at the test-of-cure visit which occurred 7 to 14 days after the end of treatment.
  - All-cause mortality at day 28 was 24.0% and 25.3% for Zerbaxa and meropenem, respectively (treatment difference 1.1; 95% CI: -5.13, 7.39).
  - Clinical cure rates were 54.4% and 53.3% for Zerbaxa and meropenem, respectively (treatment difference 1.1; 95% CI: -6.17, 8.29).
- For treatment of HABP/VABP, the most common adverse reactions (≥ 5%) with Zerbaxa use were increase in hepatic transaminases, renal impairment/renal failure, and diarrhea.
- The recommended dosage of Zerbaxa for adult patients with HABP/VABP is 3 grams (ceftolozane 2 grams/tazobactam 1 gram) administered every 8 hours by intravenous infusion over 1 hour for 8 to 14 days.
  - The duration of therapy should be guided by the severity and site of infection and the patient's clinical and bacteriological progress.
  - Refer to the Zerbaxa drug label for dosing for its other indications.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.